Want to see TSE:ENBI.X full AI Analyst Report?
Entheon Biomedical (ENBI.X) AI Stock Analysis
Entheon Biomedical
(CNQX:ENBI.X)
The score is weighed down primarily by weak financial performance (zero recent revenue, persistent losses, and ongoing cash burn), partially offset by a debt-free balance sheet. Technicals show short-term strength with the price above key moving averages, but overbought signals increase downside risk. Valuation remains challenging due to loss-making results and the absence of dividend support.
Entheon Biomedical (ENBI.X) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 762.24K
- Dividend Yield
- ―
- Average Volume (3M)
- 29.32K
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 1.82
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Entheon Biomedical Business Overview & Revenue Model
Company Description
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use di...
Entheon Biomedical Financial Statement Overview
Summary
Financial quality is high risk: revenue recently fell to zero, losses remain persistent, and operating/free cash flow are negative (ongoing cash burn). A debt-free balance sheet helps reduce near-term solvency risk, but equity appears vulnerable if losses persist.
Income Statement
12Very NegativeBalance Sheet
46NeutralCash Flow
18Very Negative| Breakdown | TTM | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 250.32K | 189.68K | 21.67K |
| Gross Profit | 0 | 0 | 0 | 250.32K | 189.68K | 9,130 |
| EBITDA | -281.49K | -334.22K | -318.00K | 13.99K | -3.60M | -8.21M |
| Net Income | -324.61K | -324.01K | -318.00K | -300.00K | -8.52M | -8.89M |
Balance Sheet | ||||||
| Total Assets | 353.78K | 353.78K | 185.14K | 401.08K | 769.22K | 9.98M |
| Cash, Cash Equivalents and Short-Term Investments | 321.83K | 321.83K | 136.49K | 344.63K | 680.17K | 2.05M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 29.75K | 29.75K | 39.81K | 85.33K | 154.65K | 927.71K |
| Stockholders Equity | 324.03K | 324.03K | 145.33K | 315.75K | 614.57K | 9.05M |
Cash Flow | ||||||
| Free Cash Flow | -314.66K | -314.66K | -355.64K | -359.93K | -1.95M | -5.71M |
| Operating Cash Flow | -314.66K | -314.66K | -355.64K | -359.93K | -1.95M | -5.62M |
| Investing Cash Flow | 0 | 0 | 0 | 24.40K | 585.64K | -98.87K |
| Financing Cash Flow | 500.00K | 500.00K | 147.50K | 0 | 0 | 4.98M |
Entheon Biomedical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ENBI.X, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ENBI.X.
Entheon Biomedical Peers Comparison
Overall Rating
- TSE:ENBI.X44Neutral
TSE:BETR43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:ENBI.X | 44Neutral | CAD 762.24K | -4.27 | -78.74% | ― | ― | ― |
| TSE:BETR | 43Neutral | CAD 154.50M | -11.36 | 34.90% | ― | ― | -266.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:ENBI.X | Entheon Biomedical Corp. | 0.06 | -0.04 | -42.11% | |
| TSE:BETR | Betterlife Pharma Inc. | 0.25 | 0.19 | 316.67% | |
| TSE:HAVN | Havn Life Sciences Inc | 0.03 | 0.00 | 0.00% | |
| TSE:MYND | Mynd Life Sciences Inc | 0.07 | 0.00 | 0.00% | |
| TSE:IBO | Universal Ibogaine Inc | 0.01 | 0.00 | 0.00% | |
| TSE:MBIO | Mindbio Therapeutics Corp. | 0.10 | -1.90 | -94.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026